The loss of Arrowhead Pharmaceuticals under GAAP for 3 months of fiscal year 2022 was $62.87 million, a 3-fold increase from $20.732 million in the previous year. Revenue increased 28.8% to $27.439 million from $21.303 million a year earlier.
The loss of Arrowhead Pharmaceuticals under GAAP for 3 months of fiscal year 2022 was $62.87 million, a 3-fold increase from $20.732 million in the previous year. Revenue increased 28.8% to $27.439 million from $21.303 million a year earlier. 
ir.arrowheadpharma.com
English (US) 